Table 3 Clinical manifestations of African American versus Caucasian patients with anti-topo I
| Â | Caucasian (n= 15) | African American (n= 8) | P |
|---|---|---|---|
Age (yr, mean ± SD) | 56.5 ± 11.5 | 45.9 ± 13.2 |  |
Male | 20% | 38% | Â |
Anti-U1RNP | 13% | 50% | 0.13 |
Anti-Sm | 0 | 25% | Â |
Proximal scleroderma | 87% | 38% | 0.03 |
No skin changes | 7% | 38% | 0.03a |
Sclerodactyly only | 7% | 25% | Â |
Pitting scar | 80% | 88% | Â |
ILD | 73% | 75% | Â |
Scleroderma kidney | 20% | 0 | Â |
Overlap with SLE | 0 | 38% | 0.03 |
Elevated CPK | 7% | 50% | 0.03 |
Overlap with PM/DM | 0 | 25% | 0.05 |